Product Description
Mechanisms of Action: Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: Eastern America
Company CEO: Robert B. Ford
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Renal Cell Carcinoma|Pancreatic Cancer|Peritoneal Cancer|Ovarian Cancer|Melanoma|Non-Small-Cell Lung Cancer
Phase 1: Macular Degeneration|Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00782093 |
M200 | P1 |
Completed |
Macular Degeneration |
2012-06-01 |
2019-03-18 |
Treatments |
|
NCT00654758 |
M200-1211 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2010-05-01 |
2019-03-18 |
||
NCT00666692 |
M200-1212 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2008-10-01 |
2019-03-18 |
||
2007-003984-33 |
2007-003984-33 | P2 |
Terminated |
Peritoneal Cancer|Ovarian Cancer |
2010-01-21 |
2025-06-29 |
Treatments |
|
2007-000509-31 |
2007-000509-31 | P2 |
Completed |
Ovarian Cancer|Peritoneal Cancer |
2009-10-20 |
2022-03-12 |
Patient Enrollment|Treatments |
|
NCT00635193 |
206OC202 | P2 |
Completed |
Ovarian Cancer|Peritoneal Cancer |
2008-10-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
2004-004243-21 |
2004-004243-21 | P2 |
Completed |
Pancreatic Cancer |
2008-06-24 |
2022-03-12 |
Treatments |
|
NCT00401570 |
M200-1205 | P2 |
Completed |
Pancreatic Cancer |
2008-06-01 |
2019-03-21 |
Treatments |
|
NCT00516841 |
206OC201 | P2 |
Terminated |
Ovarian Cancer|Peritoneal Cancer |
2008-04-01 |
2019-03-21 |
Treatments |
|
NCT00369395 |
206-MM-201 | P2 |
Terminated |
Melanoma |
2008-03-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT00100685 |
M200-1204 | P2 |
Terminated |
Renal Cell Carcinoma |
2007-12-01 |
2019-03-21 |
Treatments |
|
NCT00099970 |
M200-1203 | P2 |
Completed |
Melanoma |
None |
2019-03-21 |
Treatments |
|
NCT00278187 |
CDR0000453542 | P2 |
Unknown status |
Non-Small-Cell Lung Cancer |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/01/2021 |
PubMed |
Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. |
|
10/20/2020 |
PubMed |
Protein-driven mechanism of multiorgan damage in COVID-19. |